Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Clinical Trial Enrollment

- PMLiVE

Selfie campaign boosts cancer funds

Raises more than £8m for cancer charities

- PMLiVE

Gilead taken to task over Sovaldi pricing

US politicians question high cost of new hepatitis C drug

- PMLiVE

Pfizer’s meningitis vaccine ‘a breakthrough’

FDA to speed up review process for bivalent rLP2086

Lilly launches online training to boost patient voice in HTA

New tool aims to help patient advocates 'better influence decisions'

- PMLiVE

Ben Fisher to lead Hive’s med ed agency

He joins Pollen from Ogilvy Healthworld

- PMLiVE

Stargazing in biotech

How to spot the stars of your development portfolio and identify the winning products of the future

- PMLiVE

Celgene gets FDA OK for first oral psoriatic arthritis drug

Otezla wins US approval to treat the auto-immune disease

- PMLiVE

EMA backs Janssen rare disease drug for approval

Castleman's disease treatment Sylvant wins CHMP recommendation

- PMLiVE

Boehringer/Lilly’s empagliflozin among CHMP recommendations

If approved it will be marketed as Jardiance

- PMLiVE

Cancer Drugs Fund adds Roche, Celgene and Exelixis drugs

Avastin, Abraxane and Cometriq will be funded in certain indications

National Institute for Health and Care Excellence NICE logo

Mixed cancer news from NICE

Agency backs Janssen’s myeloma drug but denies Bayer’s Xofigo in prostate cancer

- PMLiVE

Why we must protect future innovation opportunities

Ahead of the ABPI's annual conference on 10 April, CEO Stephen Whitehead looks at securing a future for innovative medicines

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links